CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
AroCell TK 210 ELISA can now be used on automated platforms

AroCell TK 210 ELISA can now be used on automated platforms

Quantification of Thymidine Kinase 1 in serum with AroCell TK 210 ELISA is now validated for use on an open automation platform for ELISA. This enhances the application and use of the assay. We have now validated AroCell TK 210 ELISA for use on an automation platform,...

Redeye interview with Michael Brobjer

A new Redeye interview with Michael Brobjer, AroCell CEO, commenting interim report for the second quarter of 2020. See the interview on Redeye’s website.